Payment overview · 2025
General Payments
$1,403.45
65 reported records · 21 companies
Healthcare provider profile · identity verified
Maher A. Abdulla, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WARNER ROBINS, GA · NPI 1316997489
Verified facts
What the public records show
CMS Open Payments records show Maher A. Abdulla, M.D. received $1,403.45 in general payments during 2025 across 65 reported records.
Novo Nordisk Inc accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 328 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 374 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $350.41 | 25.0% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $223.73 | 15.9% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $151.72 | 10.8% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $124.89 | 8.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.06 | 4.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $63.09 | 4.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.21 | 3.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.96 | 3.7% | 3 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $44.72 | 3.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.53 | 2.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.95 | 2.2% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $27.14 | 1.9% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $26.92 | 1.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $26.30 | 1.9% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $24.20 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.70 | 1.6% | 1 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $20.73 | 1.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.98 | 1.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.00 | 1.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.05 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.16 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,403.45 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $271.80 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $151.72 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $150.42 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $150.42 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $124.89 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $63.09 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.25 | 2 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $44.72 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.98 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.98 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.98 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.08 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.53 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $27.14 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $26.30 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| Adzenys XR-ODT Normalized: adzenys xr odt |
Drug | Neos Therapeutics, LP | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.05 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 214 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 328 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 374 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
128 | 27 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
328 | 68 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
374 | 80 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
214 | 50 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 946 | 252 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 624 | 129 |
| Losartan Potassium | Losartan Potassium | 584 | 159 |
| Omeprazole | Omeprazole | 524 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 492 | 142 |
| Gabapentin | Gabapentin | 486 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 388 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 376 | 103 |
| Ozempic | Semaglutide | 374 | 80 |
| Alprazolam | Alprazolam | 360 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 338 | 84 |
| Mounjaro | Tirzepatide | 328 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 303 | 75 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 273 | 44 |
| Famotidine | Famotidine | 258 | 85 |
| Carvedilol | Carvedilol | 241 | 61 |
| Azithromycin | Azithromycin | 220 | 148 |
| Eliquis | Apixaban | 214 | 50 |
| Meloxicam | Meloxicam | 207 | 64 |
| Glimepiride | Glimepiride | 199 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 195 | 47 |
| Furosemide | Furosemide | 194 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 54 |
| Fluconazole | Fluconazole | 182 | 98 |
| Potassium Chloride | Potassium Chloride | 182 | 61 |
| Spironolactone | Spironolactone | 180 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 164 | 51 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 157 | 47 |
| Methylprednisolone | Methylprednisolone | 151 | 115 |
| Atenolol | Atenolol | 149 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 146 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 33 |
| Allopurinol | Allopurinol | 129 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 129 | 27 |
| Farxiga | Dapagliflozin Propanediol | 128 | 27 |
| Pregabalin | Pregabalin | 128 | 33 |
| Metformin Hcl Er | Metformin Hcl | 125 | 39 |
| Celecoxib | Celecoxib | 123 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 123 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 123 | 38 |
| Metformin Hcl | Metformin Hcl | 122 | 37 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 116 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 38 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 112 | 29 |
| Mirtazapine | Mirtazapine | 109 | 24 |
| Aripiprazole | Aripiprazole | 108 | 36 |
| Clonazepam | Clonazepam | 103 | 25 |
| Montelukast Sodium | Montelukast Sodium | 103 | 33 |
| Tramadol Hcl | Tramadol Hcl | 102 | 32 |
| Amoxicillin | Amoxicillin | 96 | 73 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 24 |
| Cefuroxime | Cefuroxime Axetil | 93 | 58 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 92 | 15 |
| Donepezil Hcl | Donepezil Hcl | 92 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 37 |
| Finasteride | Finasteride | 89 | 24 |
| Estradiol | Estradiol | 88 | 24 |
| Entresto | Sacubitril/Valsartan | 84 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 26 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 78 | 14 |
| Jardiance | Empagliflozin | 76 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 75 | suppressed |
| Cefdinir | Cefdinir | 74 | 63 |
| Diazepam | Diazepam | 74 | 21 |
| Trazodone Hcl | Trazodone Hcl | 74 | 27 |
| Telmisartan | Telmisartan | 73 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 18 |
| Bumetanide | Bumetanide | 70 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 20 |
| Bupropion Xl | Bupropion Hcl | 65 | 20 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 65 | 14 |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 62 | 19 |
| Ondansetron Odt | Ondansetron | 61 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 60 | 14 |
| Valacyclovir | Valacyclovir Hcl | 60 | 30 |
| Meclizine Hcl | Meclizine Hcl | 58 | 27 |
| Midodrine Hcl | Midodrine Hcl | 58 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 16 |
| Ezetimibe | Ezetimibe | 57 | 17 |
| Xarelto | Rivaroxaban | 57 | suppressed |
| Olanzapine | Olanzapine | 56 | 15 |
| Lorazepam | Lorazepam | 55 | 16 |
| Memantine Hcl | Memantine Hcl | 55 | suppressed |
| Baclofen | Baclofen | 52 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 18 |
| Lamotrigine | Lamotrigine | 50 | 17 |
| Fentanyl | Fentanyl | 49 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 48 | 13 |
| Modafinil | Modafinil | 48 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | suppressed |
| Methotrexate | Methotrexate Sodium | 46 | suppressed |
| Levetiracetam | Levetiracetam | 45 | 11 |
| Simvastatin | Simvastatin | 45 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 43 | 13 |
| Topiramate | Topiramate | 43 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 42 | 15 |
| Valsartan | Valsartan | 42 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 41 | 13 |
| Eszopiclone | Eszopiclone | 39 | suppressed |
| Torsemide | Torsemide | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 36 | 14 |
| Colchicine | Colchicine | 35 | 14 |
| Ibuprofen | Ibuprofen | 35 | 15 |
| Kerendia | Finerenone | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | 16 |
| Clonidine Hcl | Clonidine Hcl | 34 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 11 |
| Mupirocin | Mupirocin | 33 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Methadone Hcl | Methadone Hcl | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 32 | suppressed |
| Carisoprodol | Carisoprodol | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Lisinopril | Lisinopril | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Metolazone | Metolazone | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Leflunomide | Leflunomide | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | 11 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 27 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Prednisone | Prednisone | 25 | 19 |
| Primidone | Primidone | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | 11 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 17 |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Ofloxacin | Ofloxacin | 21 | 18 |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Lamotrigine Er | Lamotrigine | 20 | suppressed |
| Otezla | Apremilast | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 13 |
| Yuvafem | Estradiol | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 12 |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Sucralfate | Sucralfate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Humira(Cf) Pen | Adalimumab | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,403.45 · 65 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, AIRSUPRA, Adzenys XR-ODT, BREZTRI, COMIRNATY, ELIQUIS, EVENITY, FREESTYLE LIBRE, GEMTESA, Hillrom - Cardiac Ambulatory Monitor, KISUNLA, Kerendia, LINZESS, MOUNJARO, NUCALA, NURTEC ODT, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XYOSTED, Xelstrym, YUPELRI, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error